Capital Markets Day: Commercial Execution and Innovation in Obesity Care

10 Commercial execution and innovation Obesity care Novo NordiskⓇ The expectation is to be able to meet US demand for WegovyⓇ in the second half of 2022 WegovyⓇ simplified manufacturing process Produce ㅎ Ramp up ongoing O H 8 Filling API (in house) 1 Assemble Packing Freight Distribution Patients device (inhouse) (inhouse) CGMP issue at CMO Restart of manufacturing on track Production expected to be initiated in the second quarter of 2022 CMO expects to initiate test production (media fill) in the coming weeks Additional capacity expected to be added in 2023 CGMP: Current good manufacturing practice; FDA: Food and Drug Administration; EU: European Union; CMO: Contract Manufacturing Organisation CMD22 CAPITAL MARKETS DAY

View entire presentation